Neurotech Medical
A Blueprint for Neurological Recovery

Somewhere in Japan, inside a cutting-edge therapy room, a man in his sixties lifts two fingers on his right hand in a peace sign. A small gesture that can be easily overlooked unless you knew he once couldn’t move the right side of his body. A cerebral hemorrhage in 2023 had taken his mobility. In most hospitals, that diagnosis marks a turning point toward compromise. The goal becomes adaptation, not recovery.

But for the clinical team at Neurotech Medical, that subtle hand movement spoke volumes. It represented years of scientific perseverance, a protocol refined through relentless inquiry and an unshakable belief that paralysis need not be permanent. What the world saw as miraculous, Neurotech framed as proof that neurological restoration is not only possible but programmable.

At the heart of this possibility is ReNeuro, a proprietary therapeutic model designed not just to support the nervous system, but to retrain it. The protocol unites stem cell infusion, targeted neuromodulation and precision rehabilitation into a synchronized choreography of neuro recovery. Every intervention is deliberately calibrated to help patients adjust and reignite the brain’s capacity to rebuild.

“ReNeuro is not about coping,” says Dr. Nagatoshi Kihoin, founder and CEO of Neurotech Medical. “It’s about restoring. That distinction defines everything we do.”

Across the Asia-Pacific region, where strokes are rising in frequency and aging populations are testing the limits of traditional care, Neurotech’s model represents more than a medical breakthrough. It marks a public health pivot—a system built not around managing decline but facilitating return.

And that peace sign? It was only the beginning. After just three ReNeuro sessions, the patient stood unaided, walked and regained function in his arm and leg. In doing so, he quietly demonstrated the power of science to defy prognosis and the depth of Neurotech’s commitment to changing the narrative.

Rebuilding Circuits, Rewiring Recovery

ReNeuro is developed using Hebb’s Law, which states, ‘Neurons that fire together wire together,’ – meaning instead of waiting for the brain to develop compensatory workarounds over time, ReNeuro directly engages damaged neural circuits, retraining the brain and spinal cord with surgical precision.

But how does that rewiring happen? The protocol begins with autologous stem cells, typically harvested from the patient’s bone marrow and cultured to reach therapeutic potency. In cases where autologous extraction isn’t viable, carefully screened allogeneic cells are used, selected through rigorous immunological matching to ensure both safety and biological compatibility. Combined with regenerative cytokines and growth factors, these cells are administered intravenously to reduce neuroinflammation, enhance perfusion and prime the nervous system for repair.

Parallel to this biological preparation is a meticulously timed regimen of neuromodulation and rehabilitation, delivered by clinicians trained in Neurotech’s proprietary methods. Therapies like transcranial magnetic stimulation (TMS), functional electrical stimulation (FES) and therapeutic vibration are sequenced at the precise neurological windows when the brain is most receptive to change.

This interplay between cellular regeneration and synchronized stimulation is what transforms ReNeuro from a set of interventions into a unified neurological platform. It doesn’t just support recovery; it orchestrates it—amplifying neuroplasticity, reactivating dormant circuits and restoring movement, coordination and sensation through deliberate retraining rather than compensation.

Patients begin to recover not by learning to work around their impairments, but by reconnecting the original pathways that control movement and sensation.

“There’s nothing more powerful than watching someone walk again,” says Dr. Kihouin. “And for those of us rooted in science, watching that kind of recovery unfold is the closest thing to seeing the brain heal itself.”

The System of Second Chances

Behind every successful ReNeuro treatment is a logistical backbone designed to deliver regenerative therapy without delay. That system is KENSAI. The proprietary stem cell banking and reuse platform is designed to address one of the most pressing challenges in regenerative medicine—accessibility.

True to its name, which evokes the precision of a master swordsman, KENSAI cuts through the logistical and biological barriers of traditional cell sourcing. It allows Neurotech to collect, screen and store surplus regenerative cell lines and repurpose them for patients who are not candidates for autologous cell harvesting.

Each donated sample undergoes comprehensive infectious disease screening, genomic sequencing and human leukocyte antigen (HLA) typing to ensure safety, immunological compatibility and therapeutic integrity across diverse patient populations. This creates a centralized and diversified cell bank that significantly accelerates treatment readiness without compromising clinical standards.

But KENSAI isn’t just about logistical efficiency; it’s about clinical scalability. While autologous therapies are powerful, they are inherently limited by individual sourcing timelines. KENSAI overcomes that constraint by building a ready-to-use, ethically sourced inventory, a strategic shift that allows Neurotech to treat more patients without delay, including those in acute phases of neurological injury where time is critical.

As Neurotech expands its clinical footprint, KENSAI will serve as the cornerstone infrastructure supporting global deployment. It ensures continuity across multiple treatment sites and reinforces Neurotech’s ability to deliver regenerative care that is both personalized and widely accessible.

Results That Redefine Possibility

In a review of 986 cases involving neurotrophic stem cells, approximately 80 percent of patients reported subjective or objective improvement. Among 700 patients treated with neurotrophic factors, improvement was observed in around 60 percent—a testament to the viability and reproducibility of Neurotech’s platform across a range of neurological conditions.

From post-stroke paralysis to spinal cord injury, Neurotech’s clinical registry documents hundreds of cases that demonstrate meaningful neurological recovery, restoring functions once thought permanently lost.

Patients who once depended on wheelchairs are regaining independent gait. Stroke survivors are recovering grip strength, postural balance and the fine motor control needed for daily tasks like buttoning shirts or holding utensils.

In one documented case, a spinal cord injury patient who had lost movement in his lower limbs regained the ability to flex his hip and extend his knee following a session of ReNeuro therapy and coordinated rehabilitation. Another patient, a content creator, publicly chronicled his transformation, progressing from prosthetic reliance to navigating uneven terrain independently, offering a firsthand testament to the therapy’s impact.

Quantitative data reinforce the narrative. In a cohort of 31 stroke patients, measurable improvements in motor, sensory and balance functions were observed between the second and third rounds of stem cell administration, highlighting the cumulative efficacy of ReNeuro.

But Neurotech’s innovation doesn’t stop at therapy. It extends into how neurological recovery is monitored, predicted and personalized.

Tools such as the ReNeuro Doc checkup system, white matter lesion scoring and metabolite-based recovery prediction models add layers of data-driven precision to the care continuum. These tools enable clinicians to track recovery trajectories, adjust protocols proactively and intervene earlier when outcomes begin to deviate, ensuring that each patient’s recovery is not left to chance but guided by evidence at every step.

Technology That Sustains Momentum and Scales It

With clinical outcomes already redefining the boundaries of recovery, Neurotech is now entering its next phase of building a technology pipeline that deepens therapeutic impact and expands the reach, speed and scalability of its regenerative approach.
“If our clinical results give us the confidence to think bigger, our technology pipeline gives us the tools to act on that ambition,” says Dr. Kihouin. “The future is about scalability without clinical compromise and that’s exactly what we’re building.”

A key advancement in this evolution is the development of a nasal spray formulation of neurotrophic factors. A noninvasive, patient-friendly delivery system designed for home use.

Administered shortly before rehabilitation sessions, the spray targets neural circuits to enhance synaptic responsiveness, priming the brain and spinal cord to respond more effectively to therapeutic stimulation. It’s a seemingly simple action with profound effects, making every session more efficient and every day of therapy more meaningful.

In parallel, Neurotech is intensifying its integration of exosome-rich supernatants. Exosomes are biological signaling agents secreted alongside stem cells. They are increasingly recognized for their role in modulating inflammation, enhancing vascular perfusion and preparing injured neural tissue to integrate regenerative therapies better.

Their inclusion adds a critical layer of biochemical sophistication to the company’s already robust therapeutic toolkit

On the operations front, Neurotech’s physical footprint is growing, with active clinical programs across Tokyo, Osaka, Nagoya, Sapporo and Fukuoka. To support that growth with precision, the company is investing in AI-driven systems for predictive treatment profiling, including advanced HLA matching and metabolomic analysis. These tools will enable clinicians to identify the most compatible cell types for each patient and the optimal timing and intensity of intervention based on real-time biological markers.

For decades, neurological damage was managed through adaptation. Patients were taught to live within their limitations, often with little hope for reversal. Neurotech is pushing beyond that to restore and reconnect.

With a growing portfolio of intelligent, scalable therapeutics, Neurotech is advancing neurorehabilitation to show that what was once considered a miracle—walking and talking again—is becoming a predictable, repeatable medical reality.

This is more than innovation. It’s an infrastructure for recovery, purpose-built to give patients a second chance to live again fully. And in Neurotech Medical’s world, that isn’t a miracle. It’s medicine finally doing what it was always meant to do.